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Abstract
Objectives To determine the demographics and risk results of patients accessing a
community pharmacy diabetes risk assessment service.
Method Participating patients underwent an assessment using a validated ques-
tionnaire to determine their 10-year risk of developing type 2 diabetes. Patients
were given appropriate lifestyle advice or referred to their general practitioner if
necessary.
Key findings In total, 21 302 risk assessments were performed. Nearly one-third
(29%) of 3427 risk assessments analysed yielded a result of moderate or high chance
of developing the condition.
Conclusions Community pharmacies can identify a significant number of patients
at risk of developing type 2 diabetes in the next 10 years. Further follow-up work
needs to be done to determine the cost-effectiveness of such a service and the conse-
quences of receiving a risk assessment.
Introduction
The frequency with which the general public use the commu-
nity pharmacy[1] provides an ideal opportunity to screen
patients for undiagnosed conditions. There may be up to 1
million people in the UKwith undiagnosed type 2 diabetes,[2]
andmanymay not know they have the condition, as theymay
have few or none of the classic symptoms.[3] Opportunistic
screening tests at a random encounter with a health-care pro-
fessional can be used to identify patients with type 2 diabetes
before they start to develop complications. Alternatively,
patients can be alerted to potential risk factors to enable life-
style modification. Diabetes UK, the University of Leicester
and the University Hospitals of Leicester NHS Trust have
developed a type 2 diabetes risk assessment that uses a short
questionnaire designed to highlight a person’s risk of devel-
oping the condition over 10 years,with amoderate score indi-
cating a 1 in 7 chance and a high score indicating a 1 in 3
chance. Seen as preferable to a random capillary blood test, it
avoids false reassurance and potentially over-referral to the
general practitioner[4] and can direct people to make lifestyle
changes before the risk develops into the condition. It is a rec-
ommended first step to identifying those at risk of developing
the condition, and community pharmacists have been
encouraged to use it with their patients and customers.[5] The
aim of this service evaluation was to identify whether a
service provided by community pharmacies can identify
people at risk of developing type 2 diabetes.
Method
The University of East Anglia’s research ethics committee
approved this study as a service evaluation. The risk assess-
ment took place in all community pharmacies belonging to
one large chain across the UK. The diabetes risk assessment
involves seven simple questions along with measurements of
waist circumference and body mass index.[6] Responses to
each question are scored and combined to indicate a risk level
of developing type 2 diabetes (low, increased, moderate or
high). Professional advice is dependent on the final score and
ranges from positive feedback (low score) and simple advice
(increased risk) to advice to see one’s general practitioner for
a blood test (moderate and high risk). Further tailored advice
was given to all participants to reinforce recommended
actions. The assessment and advice were largely provided by
pharmacy assistants, who had received some electronic and
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face-to-face training. The consultation was designed to last
10 min, and consent was implied when the patient pro-
vided information to allow service participation and form
completion.
People over 18 years old, not pregnant and not previously
diagnosed with any form of diabetes were eligible for inclu-
sion. Leaflets and posters within each pharmacy were used to
advertise the service to all patients and customers.Discussion
of the service also took place in pharmacy consultations (e.g.
medicine use reviews) and within the company’s optician
stores, where the service was advertised to patients. Pharma-
cies were not paid for delivering the service.
All completed risk assessments were registered on the
pharmacy system, and the paperwork was retained. Phar-
macy teams sent a copy of the assessment to their head office
for collation. Anonymous data were then transferred to an
independent team (M.T. and D.W.) for analysis. No further
data collection or analysis is planned. All forms returned up
to September 2013 were analysed (note that the difference in
numbers is due to not all pharmacies returning the paper-
work). Descriptive analysis was performed on the data
received in the first 9 months of the service, using the SPSS v.
18 package (IBM, Armonk, USA). Medians and interquartile
ranges (IQRs) were used where the data were not normally
distributed.
Results
A total of 21 302 risk assessments in 1513 pharmacies were
recorded in the pharmacy system between the beginning of
January 2013 and the end of September 2013 (median (IQR)
6 (2–14)).A total of 3513 risk assessments were returned, and
3427with a complete dataset were analysed.Postcode analysis
on the pharmacy location demonstrated that this subsample
came from the same geographical distribution as the total
number of risk assessments performed, which was in itself
spread across the UK. The median age was 44.9 years (IQR
30.4–58.2); 30.1% of patients were male, and 86.6% were
white European. Nearly one-third (29.8%) of assessments
were performed on someone with a family history of diabe-
tes. Table 1 illustrates the results for the other questions on
the risk assessment, including the outcome score.Nearly one-
third (29.1%) of assessments yielded a result of amoderate or
high chance of developing the condition, with 60.4% being
conducted on people considered overweight or obese.
Discussion
In this particular subsample, the community pharmacy-
based risk assessment helped to identify nearly a thousand
people for whom the risk of developing type 2 diabetes was
either moderate or high, as well as a further thousand at an
increased risk of developing the condition in the next 10
years. This service demonstrates that pharmacists may be a
useful resource formany patients who do not routinely access
health services, as evidenced by the range of ages seen.
One limitation is a lack of follow-up of patients to deter-
mine their actions as a result of the assessment. Further work
should be undertaken to determinewhether lifestyle, diet and
referral advice provided to this group of people by the com-
munity pharmacy to reduce their level of risk is actually fol-
lowed by patients.Another limitation centres on the relatively
small number of assessments conducted in each pharmacy
every month and the low numbers of forms returned to be
input electronically. The return of the forms was not a prior-
ity for pharmacists, as it was not essential for service delivery,
although the company highly encouraged it. Recent research
has supported the view that risk assessment followed by a
blood test for those patients at a high risk is the most cost-
effective approach to identification.[7] However, the cost-
effectiveness of such a service in community pharmacies as
compared with screening within the medical practice (on a
population basis) remains to be established and should be the
focus of future work.
Conclusion
This evaluation has shown that pharmacists are able to iden-
tify patients who are at an increased risk of developing diabe-
tes, something that has not been demonstrated in the
literature thus far. However, it does not indicate whether this
is a cost-effective approach to risk assessment or whether
patients follow the advice provided. This should be explored
in future work.
Table 1 Profile of patients identified as a result of the diabetes risk
assessment
Parameter n Measure Result
Waist measurement 2570 Mean (SD) 88.9 cm (14.7)
Waist category 3427 % <90 cm: 55.8%
90–99.9 cm: 23.2%
100–109.9 cm: 13.0%
>110 cm: 7.9%
Body mass index 3084 Median (IQR) 26.3 (23.3–30.0)
Body mass
index range
3427 % <25: 39.6%
25–29.9: 35.4%
30–24.9: 16.7%
>35: 8.3%
Diagnosed
hypertensiona
3427 % 15.1%
Risk level 3427 % Low: 34.8%
Increased: 36.2%
Moderate: 20.0%
High: 9.1%
SD, standard deviation; IQR, interquartile range. aInformation obtained
from patient report.
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